Replies to post #212683 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

The New Patent

My understanding is this. The new US patent gives ownership rights to Anavex Life Sciences Corp in a unique, new, useful way to synthesize, chemically create the Anavex 2-73 molecule. That’s a big thing. AND, to use it to treat Alzheimer’s disease.

Many (well, most) pharmaceutical molecules are complex, with dozens of atoms and functional groups which have to be precisely arranged. One doesn’t simply mix a bit of chemical A with chemical B to have them “react” and produce the desired chemical C. That’s the stuff in the first weeks of high school chemistry. Making complex drug molecules such as Anavex 2-7 (“blarcamesine”) is not haphazard. Must be precise. Here (in one part) is what the patent tells about this:

According to an embodiment of the present disclosure, ANAVEX2-73 can be produced by charging a solution of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine free base in ethyl acetate with isopropanol. The ethylacetate is removed by distillation and the remaining isopropanol solution containing tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine free base is clear filtered. Aqueous hydrochloric acid (1.1 eq) is charged to the isopropanol solution and the formed crystalline HCl salt of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine, tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73), is isolated by filtration and dried under vacuum at 55.degree. C. for 3 days. The ANAVEX 2-73, thus obtained, is characterized by powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM), as shown in FIGS. 1-4.

But, in a more thorough reading of the entire patent, it must be noted that most of the text delineates how the drug will be used to treat Alzheimer’s disease. Anavex Life Sciences Corp now has an issued patent for that so-important application. Nobody else can use the molecule to treat Alzheimer’s.

The entire patent can be read here:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10426754.PN.&OS=PN/10426754&RS=PN/10426754

It appears to be very comprehensive.